




Cystic fibrosis (CF) (mRNA-3692 / VX-522)


Last updated 5/2/24

Modality	Program	ID #	Preclinical development	Phase 1	Phase 2	Phase 3	Commercial
 Rare disease intracellular therapeutics	Propionic acidemia (PA)	mRNA-3927	[Orange bar]				
	Methylmalonic acidemia (MMA)	mRNA-3705	[Orange bar]				
	Glycogen storage disease type 1a (GSD1a)	mRNA-3745	[Orange bar]				
	Ornithine transcarbamylase deficiency (OTC)	mRNA-3139	[Orange bar]				
	Phenylketonuria (PKU)	mRNA-3210	[Orange bar]				
 Inhaled pulmonary therapeutics	Crigler-Najjar syndrome type 1 (CN-1)	mRNA-3351	[Orange bar]				
	Cystic fibrosis (CF)*	mRNA-3692 / VX-522	[Purple bar]				
 Cardiovascular therapeutics	Relaxin	mRNA-0184	[Pink bar]				

*Vertex to pay milestone and royalties

First inhaled pulmonary mRNA therapeutic program now in clinic for Cystic Fibrosis (CF)

~5,000 patients have a mutation that does not make CFTR protein




First collaboration between Moderna and Vertex to address Cystic Fibrosis

Partner Vertex continues to enroll and dose patients in the multiple ascending dose (MAD) portion of the Phase 1/2 study of VX-522 in people with CF. Dosing in the single ascending dose (SAD) portion has been completed

Vertex expects to **share data from this study in late 2024 or early 2025**

Moderna-Vertex collaborations to address cystic fibrosis




Two parallel approaches to addressing the unmet need

(Approximately 10% of Cystic Fibrosis patients are not addressable with a CFTR modulator)


moderna

VERTEX



moderna

Science Day 2022 Summary



- We have developed a **new LNP** formulation that enables efficient delivery of mRNA to and protein expression in the **pulmonary epithelium** upon **aerosol delivery**
- Our ability to do so was enabled by building in-house systems and assays for high throughput testing of **rational LNP design** strategies
- Our optimized inhalation LNP demonstrates high levels of protein expression localized to the airway epithelium and is **well-tolerated** in rats and NHPs
- This new LNP is **well-suited for development**, with proven scale-up, stability and ability to deliver by aerosol

I Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding: Moderna's collaboration with Vertex to address cystic fibrosis; the potential of Moderna's inhalation LNP; clinical development activities; and expected timing for sharing data. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include those described in Moderna's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date referenced on the first page.